FDA Uses "Unusual" Action To Get Matrixx's Zicam Off The Market
This article was originally published in The Tan Sheet
Executive Summary
In a rare action, FDA simultaneously alerted consumers not to use Matrixx Initiatives' intranasal Zicam products because of potential safety problems and warned Matrixx to remove the products from market without first consulting with the firm
You may also be interested in...
Zicam Marketer Matrixx Tabs Another Pharma Consumer Health Veteran As CEO
Private equity firm Gryphon Investments appoints Marc Rovner, with executive experience at Pfizer, Reckitt, Unilever and BI, to helm the Zicam brand homeopathic cold remedy marketer in a shakeup that also puts consumer health care industry veterans at lead posts for sales, marketing and strategy.
Zicam Marketer Matrixx Tabs Another Pharma Consumer Health Veteran As CEO
Private equity firm Gryphon Investments appoints Marc Rovner, with executive experience at Pfizer, Reckitt, Unilever and BI, to helm the Zicam brand homeopathic cold remedy marketer in a shakeup that also puts consumer health care industry veterans at lead posts for sales, marketing and strategy.
TheraBiogen Supports Theramax Expansion With Education Push
Homeopathic firm TheraBiogen plans to roll out products “every six to nine months” to add to its existing lineup of homeopathic remedies for allergy and cold and flu, says CEO Kelly Hickel. The firm also counts on sales growth from a social media campaign to explain what is not in its products as well as what is.